Percheron Leads Mixed Healthcare Week as Devices Win New Contracts

• Percheron Therapeutics (ASX:PER) rose 66.67% after naming Michael Baker as incoming CEO ahead of a Phase II cancer trial.
• ResMed Inc. (ASX:RMD) gained 10.95% after reporting 10% fiscal 2026 revenue growth to US$5.65 billion.
• Starpharma (ASX:SPL) fell 8.23% despite raising A$32 million for its HER2-Lutetium cancer trial.
• ReNerve (ASX:RNV) added 8.11% after India approved its NervAlign nerve cuff for sale.